836 Results
Sort By:
Published on January 14, 2020
Illumina CEO Francis deSouza on Monday unveiled two new sequencing systems designed to meet growing demand for clinical genomic data at reduced cost, as well as a collaboration with Roche focused on advancing clinical diagnostics, during his presentation at the J.P. Morgan 38th Healthcare Conference in San Francisco. Illumina said its…
Published on January 13, 2020
Over the space of a few days, precision healthcare company Color announced two separate deals that further its mission of bringing low-cost, data-driven clinical genetics to health systems partners. In the first deal, announced Friday, it partnered with rural health system Sanford Health to further develop its Imagenetics program; and…
Published on January 10, 2020
ArcherDx said today it has signed a non-exclusive, multi-year commercial partnership agreement with Illumina through which the companies agreed to co-market future ArcherDX in vitro diagnostic (IVD) tests used with Illumina’s NextSeq 550Dx and MiSeq Dx sequencing systems. The value of the agreement was not disclosed. Archer said its future…
Published on January 6, 2020
Clinical genetic testing company GeneDx has announced it will adopt Bionano Genomics’ genome imaging system Saphyr to develop new assays that will eventually be used at GeneDx’s clinical laboratory in Gaithersburg, MD. “Saphyr addresses the need for more and better patient testing for diagnosis and research in drug development. GeneDx’s…
Published on December 30, 2019
Myriad Genetics’ BRACAnalysis CDx The FDA has approved Myriad Genetics’ BRACAnalysis CDx test as a companion diagnostic for the latest indication of Lynparza (olaparib) authorized by the agency. The poly ADP-ribose polymerase (PARP) inhibitor, which is co-marketed by AstraZeneca and Merck & Co., has won additional…
Published on December 24, 2019
Geisinger Health announced last week that its precision medicine project MyCode reached the milestone enrollment of 250,000 participants in Pennsylvania and New Jersey. To date, the project has both DNA sequence and health data on 145,000 of those participants and has returned medically actionable results to nearly 1,500 participants. “Geisinger…
Published on December 20, 2019
Liquid biopsy focused precision oncology company Guardant Health announced Thrusday that Medicare Administrative Contractor for the Molecular Diagnostics program finalized an expanded local coverage determination (LCD) for its flagship Guardant360 assay, making it the first liquid biopsy cancer test gain coverage for use across the majority of advanced solid tumors.…
Published on December 19, 2019
ArcherDX has completed a $55 million Series C financing round, resulting in just over one-third of the $150 million in total capital raised by the cancer diagnostics developer since it was founded in 2013. ArcherDX said it will use proceeds from the financing to expand its global commercial footprint, as…
Published on December 17, 2019
Triple negative breast cancer is one of the most difficult types of breast cancer to treat, due to the mechanism being undefined. It is negative for the three most commonly mutated breast cancer markers: HER2, estrogen receptors, and progesterone receptors. It is one of the most aggressive and deadliest types…
Published on December 4, 2019
Scientists at the Duke Cancer Institute report that they have observed how stem cell mutations quietly arise and spread throughout a widening field of the colon until they eventually predominate and become a malignancy. Working with mice, the researchers visually tagged colon cancer mutations by causing stem cells to glow.…
Published on November 29, 2019
Researchers studying the genetics of hibernating mammals have found clues associated with metabolism. Hibernating mammals became obese, insulin resistant and hyperinsulinemic to store fat in preparation for long periods of uninterrupted sleep. Yet they emerge from hibernation trim and generally healthy. In their study researchers from the University of Utah…
Published on November 22, 2019
GenapSys said it has completed a $90 million Series C financing round, with the proceeds set to fund commercialization of a namesake sequencer that according to the company will be the 100 times smaller and more affordable than current high-throughput sequencers. In addition to driving the commercial launch of the…
Published on November 21, 2019
Myriad Genetics said today that its BRACAnalysis Diagnostic System has won a third regulatory approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) that will allow physicians to determine which women with breast cancer are at risk of having Hereditary Breast and Ovarian Cancer (HBOC) syndrome—and thus eligible for…
Published on November 18, 2019
In the largest study of its kind on individuals with sudden cardiac death, researchers from Massachusetts General Hospital and the Broad Institute of MIT and Harvard performed whole-exome sequencing of 600 patients with adult-onset sudden cardiac death matched with 600 controls. They identified 5,178 genetic variants classifying 14 as pathogenic…
Published on November 6, 2019
There is little doubt that the field of genetic counseling has undergone monumental changes in the past 10 or 20 years as technology has ramped up the information available from genetic testing from one or two genes per test to panels that often contain hundreds of genes. Propelled by changes…